Experience the Molbio advantage!
Molbio Diagnostics is a pioneering Indian in-vitro diagnostics (IVD) company with a global footprint. We have deep expertise in development, production, and commercialization of pathbreaking diagnostic platforms that address the clinical need gaps and are deployed at Point-of-Care (POC), resource-limited settings. Our flagship product, Truenat, has been successfully deployed across 75+ countries and has positively impacted millions of lives.
Bigtec Labs is the R&D division of Molbio and functions as an innovation engine with a multidisciplinary team of 100 scientists and engineers, who excel in translating scientific ideas into market-ready products.
Global call for EDGE
(Scaleup partnership initiative
by Molbio and Bigtec)
Are you a growth-stage startup or SME with a transformative technology looking to accelerate commercialization?
We are launching a global call to collaborate with MedTech startups and SMEs for acceleration of product development and commercialization. This is an intensive 12 week cohort program for understanding high impact technology acceleration and faster Go-To-Market (GTM) traction. Each cohort participant will receive bespoke guidance. At the end of this program, Molbio would engage with a few cohort participants for future partnerships. This would potentially involve bridge funding for product co-development, licensing, sales and distribution. The program will be conducted in hybrid mode and will involve intermittent visits to Bangalore and Goa. All expenses, including travel and stay, of the program will be borne by Molbio.
About EDGE
Rapid POC high-sensitivity immunodiagnostics (TRL 3 - 6)
1
Call Open
Application deadline
Cohort selection
Program
Selection of future partners from the cohort
1st February, 2024
15th April, 2024 5PM IST
10th June to 15th Aug 2024
End Aug 2024
Program Value
Leverage the expertise of Molbio and Bigtec to cross the ‘valleys of death’
Masterclass & Workshops
With global leaders in the public health and MedTech industry in areas of innovation, strategy, regulatory, GTM, and sales
R&D and Manufacturing
Validation and Regulatory
Technical expertise and rapid MVP to production through best-in-class DFM
Well-established global ecosystem of validation partners and regulatory expertise
Partnership Opportunity
Potential bridge funding for product co-development
Sales
Connecting with our expansive distribution network in 75+ countries
Visits
In-person workshops at Bigtec, Bangalore, and production sites at Molbio, Goa
Call Areas
Timelines
Call Open
Application deadline
1st February, 2024
Program Value
Leverage the expertise of Molbio and Bigtec to cross the ‘valleys of death’
Masterclass & Workshops
With global leaders in public health and MedTech industry in areas of innovation, strategy, regulatory, GTM and sales
Timelines
15th April, 2024 5PM IST
Program
10th June to 15th Aug 2024
Cohort selection
2nd week of May 2024
Selection of future partners from the cohort
R&D and Manufacturing
Technical expertise and rapid MVP to production through best-in-class DFM
Validation and Regulatory
Well-established global ecosystem of validation partners and regulatory expertise
Partnership Opportunity
Potential bridge funding for product co-development
Sales
Connecting with our expansive distribution network in 75+ countries
Visits
In-person workshops at Bigtec, Bangalore, and production sites at Molbio, Goa
For more information, contact us at edge@bigtec.co.in
Rapid POC screening technology for early cancer detection (TRL 3 - 6)
2
Global call for EDGE
(Scaleup partnership initiative by Molbio and Bigtec )
Are you a growth-stage startup or SME with a transformative technology looking to accelerate commercialization?
Rapid point of care (POC) high-sensitivity immunodiagnostics (TRL 3 - 6)
1
Call areas
Rapid POC screening technology for early cancer detection
(TRL 3 - 6)
2
2nd week of May 2024
Partnership Go-live
Oct 2024
For more information, contact us at edge@bigtec.co.in
End Aug 2024
Rapid POC AMR detection (including AST-Antimicrobial Susceptibility Test)
3
Rapid POC AMR detection (including AST-Antimicrobial Susceptibility Test)(TRL 3 - 6)
3
Partnership Go-live
Oct 2024